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hat Is the Effect of
igh-Quality Risk Stratification
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chocardiography and Single-Photon
mission Computed Tomography Imaging?*
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tlanta, Georgia; and Los Angeles, California
n this issue of the Journal, Metz et al. (1) provide a
ystematic review on the prognostic value of exercise myo-
ardial perfusion imaging (MPI) and echocardiography
Echo). In the field of cardiac imaging there has been a shift
rom reports on its diagnostic accuracy toward risk stratifi-
ation. These results reveal that conventional stress cardiac
maging, accounting for more than 9 million procedures
erformed annually, has an exceptionally high negative
redictive value (2). Clinical differences between Echo and
PI would not be detectable given annual rates of ischemic
eath or myocardial infarction of 0.5%. This “warranty
eriod” provides tremendous reassurance to patients and
erves as supportive evidence for a “watchful waiting”
pproach to downstream patient management (3).
See page 227
This strong evidence base for Echo and MPI is put forth
n an era where growth in medical imaging has come under
ntense scrutiny (4,5). Territorial conflicts between imaging
pecialists (i.e., radiologists and cardiologists) have focused
n the tremendous growth in cardiac imaging as driving
xcessive health care costs. Several reports by Levin et al.
4,5) have described “unwarranted” use of cardiovascular
maging by cardiologists compared with radiologists. In a
eport using 1998Medicare beneficiary files, they found that
cho accounted for 63% of all cardiovascular imaging and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Emory Program in Cardiovascular Outcomes Research and Epidemi-
logy, Emory University School of Medicine, Atlanta, Georgia; and the ‡Cedars-r
inai Medical Center, Los Angeles, California. Dr. Shaw currently receives grant
upport from GE Healthcare.as largely performed by cardiologists (4). Similarly, utili-
ation rates for MPI grew 36% for cardiologists versus 4%
or radiologists (p  0.001) (5). Many have ascribed the
rowth in cardiac imaging to favorable procedural reim-
ursement but mostly as a consequence of self-referral by
ardiologists.
Technology assessments from the American College of
adiology (ACR) and American College of Cardiology
ACC) as well as others have become integral methods for
ayers to focus acceptable utilization (6). The ACR has for
ears developed easy-to-use appropriateness criteria relying
n expert opinion to guide indications for use of MPI and
ther imaging techniques (6). By comparison, the ACC has
argely devised clinical guidelines and expert consensus
tatements for evidence synthesis, although appropriateness
riteria for MPI were recently published (7). Although one
an argue the benefit of developing criteria based on expert
pinion versus meta-analytic approaches, the report by
etz et al. (1) highlights the large and diverse prognostic
vidence supporting the effectiveness of exercise Echo and
PI with publications including 11,029 patients. Similar
vidence is available from international cohorts, multicenter
egistries, and many prospective series focusing on the
rognostic value of Echo and MPI (8–13). Technology
ithout high-quality evidence may be left behind in reim-
ursement schemes that reward excellence (e.g., pay for
erformance).
However, what lies behind this discussion on imaging
tilization is how to define acceptable growth for a given
rocedure. One critical piece of information may be derived
rom population statistics noting a growing denominator of
maging candidates. Expanding population subsets include
hose with a new coronary heart disease (CHD) diagnosis or
levated pretest risk. From 1979 to 2003, the number of
atients discharged with a new CHD diagnosis increased by
6% (14). Similarly, the number of stroke survivors in-
reased from 1.5 to 2.4 million (15), and within the last
ecade the prevalence of diabetes increased by 61% and the
ncidence of end-stage renal disease nearly doubled (14,16).
The growth in cardiac imaging may also be related to
emporal changes in CHD mortality. An analysis of data
rom the Framingham Heart Study from 1950 to 1999
evealed that CHD death rates declined by 59% (17). Is it
easonable to infer that CHD mortality reductions are
artially related to greater use of diagnostic tests (18)?
ecent statements from the National Institutes of Health
orrelate reductions in CHD deaths to more intensive lipid-
owering guidelines (18–22). Using this logic, growth in
igh-quality cardiac imaging may contribute to declines in
HD mortality. The Metz et al. (1) data on cardiovascular
vent-free survival following Echo and MPI reflects com-
onplace management of patients with low- to high-risk
maging findings. Imaging is a core element of stable chest
ain management and an effective gatekeeper to coronary
evascularization resulting in improved outcomes. The pub-
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January 16, 2007:238–9 Editorial Commentished evidence put forth by Metz et al. (1) provides one link
n a reasonable chain of logic that the use of cardiac imaging
mproves outcome.
Certainly, self-referral cannot be eliminated as a factor
scalating cardiac imaging use. However, a growing at-risk
opulation and the clinical value of documenting ischemia
or therapeutic decision making cannot be eliminated as
ausative. Recently introduced health care policy initiatives
ocus on restricting testing, such as Echo and MPI, to
maging specialists. The meta-analysis published by Metz et
l. (1) highlights the high-quality evidence base for Echo
nd MPI largely developed within the cardiovascular com-
unity. Although earlier studies report differential prognos-
ic findings for Echo and MPI (23–27), as larger sample
izes were accrued we have observed a convergence of
utcome evidence. The low event rate in patients with
ormal exercise Echo and MPI supports similar post-test
anagement strategies for patients with low-risk findings.
vidence contained within this meta-analysis should curtail
ny further commentary on differences between the modal-
ties. Given the definition (6) that “an appropriate imaging
tudy is one in which the expected incremental information
. . exceeds the expected negative consequences by a suffi-
iently wide margin,” it is clear from this report by Metz et
l. (1) that dramatic growth in the field of cardiac imaging
s supported by a robust and mature evidence base noting a
igh negative predictive accuracy for exercise Echo and MPI.
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